Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

See all formats and pricing


Select Volume and Issue


Determination of Free Apolipoprotein(a) in Serum by Immunoassay and Its Significance for Risk Assessment in Patients with Coronary Artery Disease

Wolfgang Herrmann / Sabine Quast / Kai Wolter / Hartmut Eger / Stefan T. Kießig / Harry Hahmann / Jörg Kreuter / Ewald Molinari

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 37, Issue 1, Pages 21–28, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.1999.003, June 2005

Publication History

Published Online:


This paper describes a new enzyme-linked ligand sorbent assay (ELLSA) to quantify free apolipoprotein(a) (apo(a)). The new test immobilizes free apo(a) utilizing a specific peptide that carries the amino acid sequence of a non-covalent apo(a) binding site on apoB3375–3405 (ligand-peptide). The ligand-peptide coupled to Sepharose was used in affinity chromatography to separate free apo(a) from whole serum. Isolated free apo(a) consisted of full length apo(a) and smaller apo(a). Additionally, free apo(a) levels determined by ELLSA as well as by electroimmunodiffusion correlated moderately well. Significantly increased serum concentrations of free apo(a) were found in coronary artery disease. The mean value of free apo(a) was three times higher in patients than in controls while the lipoprotein(a) (Lpla)) concentration was doubled. Utilizing receiver operating characteristic diagrams, it was shown that the free apo(a)-ELLSA had a better diagnostic test performance in atherosclerotic risk assessment than the Lp(a)-test: specificity free apo(a)-ELLSA 0.77, Lp(a)-test 0.81 [with (a:a)-enzyme immunoassay (EIA)] to 0.83 [with (a:B)-EIA]; sensitivity free apo(a)-ELLSA 0.57, Lp(a)-test 0.36 to 0.40. In conclusion, the new free apo(a)-ELLSA allows for the specific quantification of free apo(a). This provides an interesting indicator for atherosclerotic risk assessment.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

K. M. Kostner, W. Marz, and G. M. Kostner
European Heart Journal, 2013, Volume 34, Number 42, Page 3268
Audrey O.T. Lau, Alias J. Smith, Mark T. Brown, and Patricia J. Johnson
Molecular and Biochemical Parasitology, 2006, Volume 150, Number 1, Page 56
Jean-Pierre Knapp and Wolfgang Herrmann
Clinical Chemistry and Laboratory Medicine, 2004, Volume 42, Number 9

Comments (0)

Please log in or register to comment.